研究者詳細 - 枝村　康平

論文 - 枝村　康平

分割表示 224 件中 181 - 200 件目／全件表示 >>

Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: Multicentre, randomized, open-label trial 査読

Takuya Sadahira, Okayama Urological Research Group (OURG), Koichiro Wada, Motoo Araki, Ayano Ishii, Atsushi Takamoto, Yasuyuki Kobayashi, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu, Hiromi Kumon, Teruaki Akaeda, Nobuyuki Akazawa, Naoki Akebi, Daiji Araki, Tohru Araki, Ryoji Arata, Yuichi Ariyoshi, Eiichi Ando, Nobuyoshi Ando, Kazushi Ishii, Tsutomu Ishikawa, Noritaka Ishito, Takaharu Ichikawa, Takaaki Inoue, Miyabi Inoue, Yosuke Inoue, Shin Irie, Takehiro Iwata, Tatsuya Uesugi, Shinya Uehara, Katsutoshi Uematsu, Satoshi Uno, Kohei Edamura, Shin Ebara, Yuko Oiwa, Tadashi Oeda, Teruhisa Ohashi, Yozo Ohashi, Hideo Ozawa, Junzo Ochi, Noriaki Ono, Seiji Kai, Haruki Kaku, Satoshi Katayama, Yasuhiro Katayama, Tetuzo Kaneshige, Keiichiro Kawauchi, Masashi Kawaguchi, Tatsushi Kawada, Taiki Kanbara, Mikio Kishi, Ryo Kishimoto, Nobuyuki Kusaka, Norihiro Kusumi, Kimito Kunitomi, Risa Kubota, Hiroaki Kurahashi, Hironori Kojima, Tomoko Kobayashi, Makoto Kobuke, Katsuyoshi Kondo, Takashi Saika, Kazuma Sakaeda, Koji Sakuramoto, Shinichi Sako, Tomoko Sako, Taketo Sasaoka, Katsumi Sasaki, Yoshimasa Jo, Morito Sugimoto, Yuko Seno, Akira Takao, Kosuke Takamura, Kousuke Takamura, Hitoshi Takamoto, Katsuji Takeda, Tadasu Takenaka, Daisuke Tanaka, Ryuta Tanimoto, Masaya Tsugawa, Tomoyasu Tsushima, Hiromu Tsuboi, Syunji Tojo, Kenji Tokinaga, Yusuke Tominaga, Keisuke Doi, Atsushi Nagai, Hirochika Nakajima, Tetsuya Nakada, Hirokazu Nakatsuka, Aya Nakamura, Yasuki Nakayama, Yoshitsugu Nasu, Daisuke Nishikawa, Jun Nishiguchi, Yoshio Nishitani, Shingo Nishimura, Motoichi Nishimura, Yasuhiro Nishiyama, Hajime Nibuno, Kunihiro Nozaki, Hiroyuki Nose, Gaku Noda, Hideaki Hashimoto, Kazuhiro Hata, Toshihide Hayashi, Nobuki Hayashi, Syunji Hayata, Ryoei Hara, Takeshi Hirata, Tomohiro Fujii, Kei Fujio, Ryuji Fujita, Kensuke Bekku, Takanori Maehara, Yoshio Maki, Yuko Matsumoto, Daisuke Manabe, Yusuke Mayumi, Yuki Maruyama, Yosuke Mitsui, Sadayuki Miyaji, Syuhei Munemasa, Wataru Murao, Takanori Murakami, Tadashi Murata, Akihiro Mori, Akira Morita, Koichi Monden, Tomoya Yamasaki, Masahiro Yamashita, Daiduke Yamada, Toyoko Yamato, Toru Yamane, Tomoaki Yamanoi, Yasuo Yamamoto, Kazuaki Yukari, Teruhiko Yokoyama, Takashi Yoshioka, Yuichi Watanabe

Journal of Antimicrobial Chemotherapy 72 ( 2 ) 529 - 534 2017年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Oxford University Press

Background: Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren pivoxil is an oral, β-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria. Objectives: To evaluate the clinical and microbiological efficacies of cefditoren pivoxil against acute uncomplicated cystitis and to determine the optimal duration of cefditoren pivoxil treatment. Methods: We compared 3 and 7 day regimens of cefditoren pivoxil in a multicentre, randomized, open-label study. Results: A total of 104 female patients with acute uncomplicated cystitis were enrolled and randomized into 3 day (n=51) or 7 day (n=53) treatment groups. At first visit, 94 bacterial strains were isolated from the 104 participants of which 81.7% (85/104) were E. coli. Clinical and microbiological efficacies were evaluated 5-9 days following administration of the final dose of cefditoren pivoxil. The clinical efficacies of the 3 and 7 day groups were 90.9% (40/44) and 93.2% (41/44), respectively (P=1.000). The microbiological efficacies of the 3 and 7 day groups were 82.5% (33/40) and 90.2% (37/41), respectively (P=0.349). There were no adverse events due to cefditoren pivoxil treatment, with the exception of a mild allergic reaction in one patient, after which the cefditoren pivoxil was exchanged for another antimicrobial. Conclusions: Cefditoren pivoxil is safe and effective for uncomplicated cystitis, with no significant differences in clinical and microbiological efficacies between 3 and 7 day regimens.

DOI： 10.1093/jac/dkw424

Scopus

PubMed

researchmap

Feasibility of robot-assisted radical prostatectomy in elderly patients: Comparative analysis of the peri-surgical/oncological outcomes with younger patients. 査読

Takehiro Iwata, Takashi Saika, Kohei Edamura

JOURNAL OF CLINICAL ONCOLOGY 34 ( 2 ) 2016年1月

Introduction of robot-assisted radical prostatectomy: Outcomes of a cohort comprising the initial 100 patients compared with those of patients who underwent laparoscopic radical prostatectomy

Takashi Saika, Nobuyuki Kusaka, Kohei Edamura, Kyohei Kurose, Kazuaki Yukari, Tomoya Yamasaki, Fumihito Koizumi, Keiichiro Kawauchi

Nishinihon Journal of Urology 76 ( 11 ) 408 - 413 2014年11月

記述言語：日本語掲載種別：研究論文（学術雑誌）出版者・発行元：The West Japan Urological Association

In Japan, the modalities of radical prostatectomy are changing drastically due to recent innovation of the Japanese social health insurance system regarding surgery for prostate cancer (PCa). We compared outcomes between a cohort comprising the initial 100 patients who underwent robot-assisted radical prostatectomy (RALP) and patients who had undergone laparoscopic radical prostatectomy (LRP). Between September 2012, when we initiated RALP, and September 2013, we performed this operation on 100 patients. All the surgeries were undertaken by a single surgical team conducted by the Director of the Department of Urology. Peri-surgical outcomes, pathological findings and continence status were compared with those of 141 patients who had undergone LRP. Preoperative parameters (age, PSA, Gleason score) were similar in both the RALP and LRP groups. Operative time (169 vs. 209 minutes) and estimated blood loss (minimal vs. 77 ml) were reduced in the RALP group vs. the LRP group. Peri-operative complications in the RALP group appeared to be minimal, with no cases of intra-operative open conversion. On the other hand, severe complications, including 3 rectal injuries, were observed in 6 cases in the LRP group. Although not statistically significant, there was a lower positive margin rate in organ-confined (pT2) disease (7.1%, RALP vs. 16%, LRP). Continence at 1 month was 76% following RALP as opposed to 41% after LRP. The transition to RALP from LRP has yielded superior operative, oncologic, and functional results.

Scopus

researchmap

Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer. 国際誌

Theodoros Karantanos, Ryuta Tanimoto, Kohei Edamura, Takahiro Hirayama, Guang Yang, Alexei A Golstov, Jianxiang Wang, Shinji Kurosaka, Sanghee Park, Timothy C Thompson

International journal of cancer 134 ( 8 ) 2003 - 13 2014年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

GLIPR1 is a p53 target gene known to be downregulated in prostate cancer, and increased endogenous GLIPR1 expression has been associated with increased production of reactive oxygen species, increased apoptosis, decreased c-Myc protein levels and increased cell cycle arrest. Recently, we found that upregulation of GLIPR1 in prostate cancer cells increases mitotic catastrophe through interaction with heat shock cognate protein 70 (Hsc70) and downregulation of Aurora kinase A and TPX2. In this study, we evaluated the mechanisms of recombinant GLIPR1 protein (glioma pathogenesis-related protein 1-transmembrane domain deleted [GLIPR1-ΔTM]) uptake by prostate cancer cells and the efficacy of systemic GLIPR1-ΔTM administration in a prostate cancer xenograft mouse model. GLIPR1-ΔTM was selectively internalized by prostate cancer cells, leading to increased apoptosis through reactive oxygen species production and to decreased c-Myc protein levels. Interestingly, GLIPR1-ΔTM was internalized through clathrin-mediated endocytosis in association with Hsc70. Systemic administration of GLIPR1-ΔTM significantly inhibited VCaP xenograft growth. GLIPR1-ΔTM showed no evidence of toxicity following elimination from mouse models 8 hr after injection. Our results demonstrate that GLIPR1-ΔTM is selectively endocytosed by prostate cancer cells, leading to increased reactive oxygen species production and apoptosis, and that systemic GLIPR1-ΔTM significantly inhibits growth of VCaP xenografts without substantial toxicity.

DOI： 10.1002/ijc.28529

PubMed

researchmap

LAPAROSCOPY AND ENDOSCOPY COOPERATIVE SINGLE-SITE SURGERY (LECS) FOR BLADDER ENDOMETRIOSIS DISSECTION 査読

Kyouhei Kurose, Tomoya Yamasaki, Kazuaki Yukari, Kohei Edamura, Nobuyuki Kusaka, Takashi Saika

JOURNAL OF ENDOUROLOGY 26 A504 - A504 2012年9月

Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer. 国際誌

Tatsuya Uesugi, Takashi Saika, Kohei Edamura, Hiroyuki Nose, Makoto Kobuke, Shin Ebara, Fernand Abarzua, Norihisa Katayama, Hiroyuki Yanai, Yasutomo Nasu, Hiromi Kumon

International journal of radiation oncology, biology, physics 82 ( 2 ) e219-23 2012年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

PURPOSE: To reveal a predictive factor for biochemical recurrence (BCR) after permanent prostate brachytherapy (PPB) using iodine-125 seed implantation in patients with localized prostate cancer classified as low or intermediate risk based on National Comprehensive Cancer Network (NCCN) guidelines. METHODS AND MATERIALS: From January 2004 to December 2009, 414 consecutive Japanese patients with clinically localized prostate cancer classified as low or intermediate risk based on the NCCN guidelines were treated with PPB. The clinical factors including pathological data reviewed by a central pathologist and follow-up data were prospectively collected. Kaplan-Meier and Cox regression analyses were used to assess the factors associated with BCR. RESULTS: Median follow-up was 36.5 months. The 2-, 3-, 4-, and 5-year BCR-free rates using the Phoenix definition were 98.3%, 96.0%, 91.6%, and 87.0%, respectively. On univariate analysis, the Gleason score, especially primary Gleason grade 4 in biopsy specimens, was a strong predicting factor (p < 0.0001), while age, initial prostate-specific antigen (PSA) level, T stage, and minimal dose delivered to 90% of the prostate volume (D90) were insignificant. Multivariate analysis indicated that a primary Gleason grade 4 was the most powerful prognostic factor associated with BCR (hazard ratio = 6.576, 95% confidence interval, 2.597-16.468, p < 0.0001). CONCLUSIONS: A primary Gleason grade 4 carried a worse BCR prognosis than the primary grade 3 in patients treated with PPB. Therefore, the indication for PPB in patients with a Gleason sum of 4 + 3 deserves careful and thoughtful consideration.

DOI： 10.1016/j.ijrobp.2011.04.018

PubMed

researchmap

Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. 国際誌

Guang Yang, Alexei A Goltsov, Chengzhen Ren, Shinji Kurosaka, Kohei Edamura, Richard Logothetis, Francesco J DeMayo, Patricia Troncoso, Jorge Blando, John DiGiovanni, Timothy C Thompson

Molecular cancer research : MCR 10 ( 2 ) 218 - 29 2012年2月

記述言語：英語掲載種別：研究論文（学術雑誌）

Previously we reported caveolin-1 (Cav-1) overexpression in prostate cancer cells and showed that it promotes prostate cancer progression. Here, we report that Cav-1 was overexpressed in 41.7% (15 of 36) of human high-grade prostatic intraepithelial neoplasia (HGPIN) specimens obtained during radical prostatectomies. Positive correlations exist between Cav-1-positive (Cav-1(+)) HGPIN and Cav-1(+) primary prostate cancer (rho = 0.655, P < 0.0001) and between Cav-1 and c-Myc expression in HGPIN (rho = 0.41, P = 0.032). To determine whether Cav-1 cooperates with c-Myc in development of premalignant lesions and prostate cancer in vivo, we generated transgenic mice with c-Myc overexpression driven by the ARR(2)PB promoter. In this ARR(2)PB-c-myc model, Cav-1 overexpression was found in mouse PIN (mPIN) lesions and prostate cancer cells and was associated with a significantly higher ratio of proliferative to apoptotic labeling in mPIN lesions than in the Cav-1-negative epithelia adjacent to those lesions (10.02 vs. 4.34; P = 0.007). Cav-1 overexpression was also associated with increased levels of P-Akt and VEGF-A, which were previously associated with Cav-1-induced prostate cancer cell survival and positive feedback regulation of cellular Cav-1 levels, respectively. In multiple prostate cancer cell lines, Cav-1 protein (but not mRNA) was induced by c-Myc transfection, whereas VEGF siRNA transfection abrogated c-Myc-induced Cav-1 overexpression, suggesting a c-Myc-VEGF-Cav-1 signaling axis. Overall, our results suggest that Cav-1 is associated with c-Myc in the development of HGPIN and prostate cancer. Furthermore, Cav-1 overexpression in HGPIN is potentially a biomarker for early identification of patients who tend to develop Cav-1(+) primary prostate cancer.

DOI： 10.1158/1541-7786.MCR-11-0451

PubMed

researchmap

Could a salvage lymphadenectomy after chemotherapy have clinical impact on cancer survival in patients with metastatic urothelial carcinoma? 査読

Takashi Saika, Kensuke Bekku, Ryo Kishimoto, Shin Ebara, Kohei Edamura, Kyohei Kurose, Yasutomo Nasu, Hiromi Kumon

JOURNAL OF CLINICAL ONCOLOGY 30 ( 5 ) 2012年2月

Local and distant effects of caveolin-1 on prostate cancer progression

T. C. Thompson, S. A. Tahir, L. Li, M. Watanabe, K. Naruishi, G. Yang, Ken-ichi Tabata, S. Kurosaka, K. Edamura, R. Tanimoto, P. Corn, D. Kadmon, C. J. Logothetis, P. Troncoso, C. Ren, A. Goltsov, S. Park

Caveolins in Cancer Pathogenesis, Prevention and Therapy 1 - 15 2012年1月

GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. 国際誌

Guru Sonpavde, Timothy C Thompson, Rajul K Jain, Gustavo E Ayala, Shinji Kurosaka, Kohei Edamura, Ken-ichi Tabata, Chengzhen Ren, Alexei A Goltsov, Martha P Mims, Teresa G Hayes, Michael M Ittmann, Thomas M Wheeler, Adrian Gee, Brian J Miles, Dov Kadmon

Clinical cancer research : an official journal of the American Association for Cancer Research 17 ( 22 ) 7174 - 82 2011年11月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: GLIPR1 is upregulated by p53 in prostate cancer cells and has preclinical antitumor activity. A phase I clinical trial was conducted to evaluate the safety and activity of the neoadjuvant intraprostatic injection of GLIPR1 expressing adenovirus for intermediate or high-risk localized prostate cancer before radical prostatectomy (RP). METHODS: Eligible men had localized prostate cancer (T1-T2c) with Gleason score greater than or equal to 7 or prostate-specific antigen 10 ng/mL or more and were candidates for RP. Patients received the adenoviral vector expressing the GLIPR1 gene by a single injection into the prostate followed four weeks later by RP. Six viral particle (vp) dose levels were evaluated: 10(10), 5 × 10(10), 10(11), 5 × 10(11), 10(12), and 5 × 10(12) vp. RESULTS: Nineteen patients with a median age of 64 years were recruited. Nine men had T1c, 4 had T2a, and 3 had T2b and T2c clinical stage. Toxicities included urinary tract infection (n = 3), flu-like syndrome (n = 3), fever (n = 1), dysuria (n = 1), and photophobia (n = 1). Laboratory toxicities were grade 1 elevated AST/ALT (n = 1) and elevations of PTT (n = 3, with 1 proven to be lupus anticoagulant). No pathologic complete remission was seen. Morphologic cytotoxic activity, induction of apoptosis, and nuclear p27(Kip1) upregulation were observed. Peripheral blood CD8(+), CD4(+), and CD3(+) T-lymphocytes were increased, with upregulation of their HLA-DR expression and elevations of serum IL-12. CONCLUSIONS: The intraprostatic administration of GLIPR1 tumor suppressor gene expressed by an adenoviral vector was safe in men, with localized intermediate or high-risk prostate cancer preceding RP. Preliminary evidence of biologic antitumor activity and systemic immune response was documented.

DOI： 10.1158/1078-0432.CCR-11-1899

PubMed

researchmap

Tumor growth and metastasis suppression by Glipr1 gene-modified macrophages in a metastatic prostate cancer model. 国際誌

K Tabata, S Kurosaka, M Watanabe, K Edamura, T Satoh, G Yang, E Abdelfattah, J Wang, A Goltsov, D Floryk, T C Thompson

Gene therapy 18 ( 10 ) 969 - 78 2011年10月

記述言語：英語掲載種別：研究論文（学術雑誌）

We previously identified the mouse and human Glipr1 and GLIPR1/RTVP-1 genes, respectively, as direct p53 targets with proapoptotic activities in various cancer cell lines, including prostate cancer (PCa). Intratumoral injection of an adenoviral vector capable of efficient transduction and expression of Glipr1 (AdGlipr1) yielded promising therapeutic results in an orthotopic, metastatic mouse model of PCa. AdGlipr1-transduced macrophages (Mφ/Glipr1) generated greater surface expression of CD40, CD80 and major histocompatibility complex class II molecules and greater production of interleukin 12 (IL-12) and IL-6 in vitro than control macrophages did. Mechanistic analysis indicated that increased production of IL-12 in Mφ/Glipr1 depends on activation of the p38 signaling cascade. Mφ/Glipr1 injected into orthotopic 178-2BMA tumors in vivo resulted in significantly suppressed prostate tumor growth and spontaneous lung metastases and longer survival relative to those observed in control-treated mice. Furthermore, these preclinical data indicate the generation of systemic natural killer cell activity and tumor-specific cytotoxic T lymphocyte responses. Trafficking studies confirmed that intratumorally injected Mφ/Glipr1 could migrate to draining lymph nodes. Overall, our data suggest that this novel gene-modified cell approach is an effective treatment avenue that induces antitumor immune responses in preclinical studies.

DOI： 10.1038/gt.2011.51

PubMed

researchmap

PRIMARY GLEASON GRADE 4 IMPACTS ON BIOCHEMICAL RECURRENCE AFTER PERMANENT INTERSTITIAL BRACHYTHERAPY IN JAPANESE PATIENTS WITH LOW- OR INTERMEDIATE-RISK PROSTATE CANCER 査読

Takashi Saika, Tatsuya Uesugi, Kohei Edamura, Hiroyuki Nose, Makoto Kobuke, Shin Ebara, Norihisa Katayama, Hiroyuki Yanai, Yasutomo Nasu, Hiromi Kumon

JOURNAL OF UROLOGY 185 ( 4 ) E523 - E523 2011年4月

OP-302 開放的腎部分切除術55症例の臨床的検討(腎腫瘍/手術2,一般演題口演,第99回日本泌尿器科学会総会)

西村慎吾, 枝村康平, 黒瀬恭平, 江原伸, 三枝道尚

日本泌尿器科学会雑誌 102 ( 2 ) 391 - 391 2011年

Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development. 国際誌

Kai Zhang, Masami Watanabe, Yuji Kashiwakura, Shun-Ai Li, Kohei Edamura, Peng Huang, Ken Yamaguchi, Yasutomo Nasu, Yasuyuki Kobayashi, Masakiyo Sakaguchi, Kazuhiko Ochiai, Hiroshi Yamada, Kohji Takei, Hideo Ueki, Nam-Ho Huh, Ming Li, Haruki Kaku, Yanqun Na, Hiromi Kumon

International journal of oncology 37 ( 6 ) 1495 - 501 2010年12月

記述言語：英語掲載種別：研究論文（学術雑誌）

The tumor suppressor REIC/Dkk-3 is a secretory protein which was originally identified to be downregulated in human immortalized cells. In the present study, we investigated the expression pattern of REIC/Dkk-3 in various cell types to characterize its physiological functions. We first examined the expression level of REIC/Dkk-3 in a broad range of cancer cell types and confirmed that it was significantly downregulated in all of the cell types. We also examined the tissue distribution pattern in a variety of normal mouse organs. Ubiquitous REIC/Dkk-3 protein expression was observed in the organs. The expression was abundant in the liver, heart and brain tissue, but was absent in the spleen and peripheral blood mononuclear cells. The immunohistochemical analyses revealed that the subcellular localization of REIC/Dkk-3 had a punctate pattern around the nucleus, indicating its association with secretory vesicles. In cancer cells stably transfected with REIC/Dkk-3, the protein was predominantly localized to the endoplasmic reticulum (ER) under observation with confocal microscopy. Because REIC/Dkk-3 was found to be abundantly expressed in the acinar epithelial cells of the mouse prostate, we analyzed the effects of recombinant REIC/Dkk-3 protein on the acinar morphogenesis of RWPE-1 cells, which are derived from human normal prostate epithelium. Statistically significant acinar growth was observed in the culture condition with 10 µg/ml REIC/Dkk-3 protein, implicating the soluble form in prostatic acinar development. Current results suggest that REIC/Dkk-3 may play a role in regulating the morphological process of normal tissue architecture through an autocrine and/or paracrine manner.

PubMed

researchmap

A PHASE I/II STUDY OF ADENOVIRUS-MEDIATED INTERLEUKIN-12 GENE THERAPY FOR HORMONE REFRACTORY PROSTATE CANCER; A REPORT OF INITIAL 6 CASES 査読

Katsumi Sasaki, Yasutomo Nasu, Haruki Kaku, Masami Watanabe, Kohei Edamura, Takashi Saika, Hiromi Kumon, Malcolm K. Brenner

JOURNAL OF GENE MEDICINE 12 ( 12 ) 1025 - 1025 2010年12月